Adagene Inc. ADAG
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Adagene Inc. (ADAG) is a healthcare company listed in the US with a market value of about $113M. In fiscal year 2025 it had revenue of $8M and net income of -$18M, a net margin of -229.6%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 61% a year, a 5-year average ROIC of -43%.
About Adagene
Adagene is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $2M in 2018 to $8M in 2025, growth of about 26.1% a year. It was profitable in 0 of the last 8 years in our data. It spends 287% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $103204 | $18M | $9M | $10M | $700913 | $480000 | $2M |
| Net income | -$18M | -$33M | -$19M | -$80M | -$73M | -$42M | -$16M | -$15M |
| Free cash flow | -$16M | -$30M | -$29M | -$49M | -$46M | -$29M | -$18M | -$15M |
| EPS (diluted) | $-0.27 | $-0.51 | $-0.29 | $-1.21 | $-1.11 | $-0.64 | $-0.25 | $-0.23 |
| Net margin | -229.6% | -32386.5% | -104.6% | -860.6% | -719.2% | -6048.9% | -3423.4% | -1010.2% |
| ROIC | -50.7% | -52.1% | -20.2% | -59.7% | -34.8% | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Adagene pay a dividend?
Not currently.
Is Adagene a good stock to buy?
We do not give buy or sell advice. Adagene scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.